Veru Inc is trading 5.6% down at $3.21 in after-hours trading as investors continue to take profits following a massive rally triggered by its clinical trial supply agreement with Novo Nordisk.
- The stock fell 19.6% during regular trading on June 5, dropping from $4.23 to $3.40 after an 88% jump the previous Thursday.
- The extended decline in after-hours suggests ongoing profit-taking rather than any new company-specific catalysts or negative news.
- The recent volatility follows the announcement of a supply deal for enobosarm to be used in combination with Novo Nordisk's weight-loss treatments.